Dec 62022

Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication

December 6th, 2022|Categories: Featured, Investor News, News, Press Releases|Tags: , , , , |

Halberd’s method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains. Jackson Center, PA December 6, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB).  Halberd will utilize its laser eradication technology which successfully  eradicated numerous Gram-Negative bacteria whose results were reported in an October 18, 2022 press release.  Gram-negative bacteria ...

Dec 52022

“The Street Podcast” Features Halberd’s “Groundbreaking” Cancer Treatment Approach. Listen Now!

December 5th, 2022|Categories: Featured, Investor News, Medical, News|Tags: , , , , , , |

CEO William Hartman and CTO Mitchell Felder report successful application of Halberd’s patented methodology for Cancer Antigen Eradication Treatment. Jackson Center, PA December 5, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments, successfully eradicating Cancer disease antigens”. Listen here: Dr. Mitchell S. Felder, Halberd’s Chief Technology Officer and a board-certified attending neurologist ...

Nov 302022

Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant

November 30th, 2022|Categories: Featured, Investor News, Medical, News|Tags: , , , , |

UPDATED. Boosts effectiveness by 44.4%% of commercially available Covid antibody in cocktail Jackson Center, PA November 30, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Covid research has led to a scientific article titled, “A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant.”  The article has been peer reviewed and accepted for publication, but has not yet been published. The paper describes the Halberd sponsored research which resulted ...

Nov 172022

Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint By Eradicating Cancer Disease Antigen Linked to Breast Cancer

November 17th, 2022|Categories: Featured, Investor News, Medical, News|Tags: , , , , , , |

Halberd Successful In Laboratory Tests In Eradicating All Five of The Top Cancer Disease Antigens Attempted To Date Jackson Center, PA, November 17, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in their latest series of tests.  Halberd had been successful previously in eradicating all five cancer disease antigens (PD-1, PDL-1, IL-6, ...

Nov 142022

Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals

November 14th, 2022|Categories: Featured, Investor News, News, Press Releases|Tags: , , , , |

Accelerated Sales of HALB's Patented Products through newly formed “The Hamden Group” Jackson Center, PA, November 14, 2022 – Halberd Corporation (OTC-PINK: HALB) has signed a contract with the Hamden Group. The Hamden Group is a newly formed corporation which consists of members of the Croden family and Darren Hamans, who have extensive experience in the sales and marketing of pharmaceutical products. Darren Hamans is a Consultant for Business Development of the Halberd Corporation.  Darren Hamans ...

Oct 182022

Halberd Laser Therapy Eliminates Over 90% of Multiple Antibiotic Resistant Bacteria in Minutes

October 18th, 2022|Categories: Investor News, Medical, News, Press Releases|Tags: , , , , , |

Could be Instrumental in Curing Sepsis, Meningitis Among Other Life-Threatening Diseases Jackson Center, PA, October 18, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has successfully eliminated various antibiotic resistant bacteria from buffer solution , in-vitro, through the use of a single designer monoclonal antibody conjoined to a metallic nanoparticle which attaches to the bacteria.  The combined bacteria-antibody-nanoparticle cluster are then exposed to laser emissive energy.  In lab testing, over 90% of each bacteria was eliminated in ...

Go to Top